Portal de Periódicos da CAPES

Mycosis fungoides and S ézary syndrome: Current challenges in assessment, management and prognostic markers

2015; Wiley; Volume: 57; Issue: 3 Linguagem: Inglês

10.1111/ajd.12349

1440-0960

Charlotte FM Hughes, Kate Newland, Christopher McCormack, Stephen Lade, H. Miles Prince,

Lymphoma Diagnosis and Treatment

Abstract Mycosis fungoides and S ézary syndrome are the most common variants of the cutaneous T ‐cell lymphomas. Assessment of a patient with a suspected diagnosis requires thorough history taking and physical examination, in combination with skin biopsy. In some cases flow cytometry, molecular studies and imaging are also required in order to diagnose and stage the disease. Staging is derived from the tumour‐node‐metastasis‐blood classification and is currently our best attempt to stratify prognosis and hence guide management in this complex disease. Many other clinical, biological and pathological factors may help to distinguish groups at risk and predict prognosis more accurately. Management remains heavily guided by staging, such that patients with early‐stage disease generally begin treatment with skin‐directed or local therapies and those with advanced‐stage disease have many treatment options, including chemotherapy, the use of biological agents, local and total body radiotherapy, as well as haematopoietic stem cell transplantation. Besides staging, many other patient‐related factors influence the treatment strategy, particularly where symptom relief is paramount. There are many challenges remaining in the study of Mycosis fungoides and S ézary syndrome and, given the rarity of the disease, concerted worldwide efforts are required to conduct efficient and effective research.